77 related articles for article (PubMed ID: 19141538)
1. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking.
Kimberley FC; van Bostelen L; Cameron K; Hardenberg G; Marquart JA; Hahne M; Medema JP
FASEB J; 2009 May; 23(5):1584-95. PubMed ID: 19141538
[TBL] [Abstract][Full Text] [Related]
2. Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties.
Schuepbach-Mallepell S; Das D; Willen L; Vigolo M; Tardivel A; Lebon L; Kowalczyk-Quintas C; Nys J; Smulski C; Zheng TS; Maskos K; Lammens A; Jiang X; Hess H; Tan SL; Schneider P
J Biol Chem; 2015 Jun; 290(26):16330-42. PubMed ID: 25953898
[TBL] [Abstract][Full Text] [Related]
3. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
[TBL] [Abstract][Full Text] [Related]
4. TACI and endogenous APRIL in B cell maturation.
Garcia-Carmona Y; Fribourg M; Sowa A; Cerutti A; Cunningham-Rundles C
Clin Immunol; 2023 Aug; 253():109689. PubMed ID: 37422057
[TBL] [Abstract][Full Text] [Related]
5. The APRIL paradox in normal versus malignant B cell biology.
van Attekum MH; Kater AP; Eldering E
Cell Death Dis; 2016 Jun; 7(6):e2276. PubMed ID: 27336720
[No Abstract] [Full Text] [Related]
6. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.
Guadagnoli M; Kimberley FC; Phan U; Cameron K; Vink PM; Rodermond H; Eldering E; Kater AP; van Eenennaam H; Medema JP
Blood; 2011 Jun; 117(25):6856-65. PubMed ID: 21543761
[TBL] [Abstract][Full Text] [Related]
7. The BAFF-APRIL System in Cancer.
Ullah MA; Mackay F
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980677
[TBL] [Abstract][Full Text] [Related]
8. Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival.
Reijmers RM; Groen RW; Kuil A; Weijer K; Kimberley FC; Medema JP; van Kuppevelt TH; Li JP; Spaargaren M; Pals ST
Blood; 2011 Jun; 117(23):6162-71. PubMed ID: 21471524
[TBL] [Abstract][Full Text] [Related]
9. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y; Hao H; Wang Z; Ong CY; Dutcher R; Xu Y; Liu J; Pedersen LC; Xu D
Elife; 2024 Jan; 12():. PubMed ID: 38265424
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis.
Luo Y; Hao H; Wang Z; Ong C; Dutcher R; Xu Y; Liu J; Pedersen LC; Xu D
bioRxiv; 2023 Nov; ():. PubMed ID: 37546770
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of adjuvants effects on neonatal plasma cell survival niche in bone marrow and persistence of humoral immune responses.
Aradottir Pind AA; Thorsdottir S; Magnusdottir GJ; Meinke A; Del Giudice G; Jonsdottir I; Bjarnarson SP
Front Immunol; 2022; 13():904415. PubMed ID: 35990686
[TBL] [Abstract][Full Text] [Related]
12. Advanced Molecular Dynamics Approaches to Model a Tertiary Complex APRIL/TACI with Long Glycosaminoglycans.
Marcisz M; Maszota-Zieleniak M; Huard B; Samsonov SA
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572563
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.
Romano A; Storti P; Marchica V; Scandura G; Notarfranchi L; Craviotto L; Di Raimondo F; Giuliani N
Front Oncol; 2021; 11():684561. PubMed ID: 34307150
[TBL] [Abstract][Full Text] [Related]
14. Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily.
Kucka K; Wajant H
Front Cell Dev Biol; 2020; 8():615141. PubMed ID: 33644033
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
16. Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells.
Nguyen DC; Joyner CJ; Sanz I; Lee FE
Front Immunol; 2019; 10():2138. PubMed ID: 31572364
[TBL] [Abstract][Full Text] [Related]
17. No interactions between heparin and atacicept, an antagonist of B cell survival cytokines.
Kowalczyk-Quintas C; Willen D; Willen L; Golob M; Schuepbach-Mallepell S; Peter B; Eslami M; Vigolo M; Broly H; Samy E; Yalkinoglu Ö; Schneider P
Br J Pharmacol; 2019 Oct; 176(20):4019-4033. PubMed ID: 31355456
[TBL] [Abstract][Full Text] [Related]
18. Isolation and functional analysis of syndecans.
Park PW
Methods Cell Biol; 2018; 143():317-333. PubMed ID: 29310785
[TBL] [Abstract][Full Text] [Related]
19. The Role of BAFF System Molecules in Host Response to Pathogens.
Sakai J; Akkoyunlu M
Clin Microbiol Rev; 2017 Oct; 30(4):991-1014. PubMed ID: 28855265
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.
Wallach D
Cold Spring Harb Perspect Biol; 2018 Oct; 10(10):. PubMed ID: 28847899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
